Provides the prescription label for mifepristone or misoprostol may include the address of the dispensing health care practice and shall include the address of the prescribing health care practice at the prescriber's request; provides that a health care prescriber shall inform a patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.
Summary
Bill A05285 amends the education and public health laws in New York regarding the prescription labeling of mifepristone and misoprostol. The bill allows for the prescription label to include the name or address of the dispensing health care practice instead of the name of the dispenser. Additionally, it mandates that at the prescriber's request, the label may also include the name or address of the prescribing health care practice instead of the prescriber's name. Furthermore, healthcare prescribers are required to inform patients if such changes are made to the prescription label.
Impact
The passage of this bill will modify existing regulations on prescription labeling for specific medications, potentially enhancing patient privacy by allowing the use of healthcare practice names instead of individual prescribers. This change could affect how prescriptions are processed and perceived by patients, as well as how healthcare practices communicate with their patients regarding medication dispensation.
Sentiment
The sentiment surrounding Bill A05285 appears to be generally favorable, as indicated by the voting history. The bill passed through various committees with a majority of votes in favor, culminating in a successful final passage in both the Assembly and Senate. However, there is a notable minority opposition, reflecting some concerns regarding the implications of such changes on patient identification and accountability.
Contention
Points of contention primarily revolve around the potential impacts on patient safety and accountability. Critics argue that removing the prescriber's name from the label could lead to confusion or lack of accountability in medication management. Supporters, however, emphasize the importance of patient privacy and the need for modernizing prescription practices to reflect current healthcare dynamics.
Same As
Provides the prescription label for mifepristone or misoprostol may include the address of the dispensing health care practice and shall include the address of the prescribing health care practice at the prescriber's request; provides that a health care prescriber shall inform a patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.
Provides the prescription label for mifepristone or misoprostol may include the address of the dispensing health care practice and shall include the address of the prescribing health care practice at the prescriber's request; provides that a health care prescriber shall inform a patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.
Permits prescription labels for mifepristone, misoprostol, and their generic alternatives to include the name of the prescribing health care practice instead of the name of the prescriber at the prescriber's request.
Permits prescription labels for mifepristone, misoprostol, and their generic alternatives to include the name of the prescribing health care practice instead of the name of the prescriber at the prescriber's request.
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.
An Act to Amend Maine's Prescription Drug Labeling Law by Allowing the Removal of the Name of a Prescriber of Mifepristone, Misoprostol and Their Generic Alternatives
Provides that the prescription label for medication abortion prescription drugs shall include the name of the dispensing health care practice instead of the name of the dispenser.
Provides that the prescription label for medication abortion prescription drugs shall include the name of the dispensing health care practice instead of the name of the dispenser.
Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.